Supernus Pharmaceuticals (SUPN) Expected to Announce Quarterly Earnings on Tuesday

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) is projected to announce its earnings results after the market closes on Tuesday, February 25th. Analysts expect the company to announce earnings of $0.46 per share and revenue of $155.25 million for the quarter. Investors interested in participating in the company's conference call can do so using this link.

Supernus Pharmaceuticals Stock Down 4.5 %

NASDAQ:SUPN traded down $1.54 during trading hours on Friday, reaching $33.05. 758,066 shares of the company's stock were exchanged, compared to its average volume of 435,390. The company has a market capitalization of $1.83 billion, a P/E ratio of 30.89 and a beta of 0.90. Supernus Pharmaceuticals has a 12 month low of $25.53 and a 12 month high of $40.28. The business's 50-day simple moving average is $37.48 and its two-hundred day simple moving average is $35.30.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 700 shares of the firm's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. This trade represents a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 9.30% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald cut Supernus Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $57.00 to $36.00 in a report on Wednesday.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.